LL-37 Antimicrobial Peptide Screening Form Template

LL-37 is a human cathelicidin antimicrobial peptide with immunomodulatory, wound healing, and anti-inflammatory properties. It is prescribed off-label through compounding pharmacies for patients with recurrent infections, slow-healing wounds, and immune dysfunction. LL-37 has both pro- and anti-inflammatory effects depending on context, making careful patient screening essential. This form documents immune-related symptoms and screens for contraindications including autoimmune disease and immunosuppressive therapy.

4 sections
17 fields
HIPAA-ready
3 citations

Free Template

LL-37 Peptide Screening Form

Preview Form Automate This Form
No account required to use template
Customize with your practice branding
Reviewed against HIPAA & DEA guidelines

Form Preview

This is how the form appears to patients. Customize with your practice name and branding.

Your Practice Name

LL-37 Peptide Screening Form

Preview
1

General Patient Information

Please provide your personal information.

First Name

Jane

Last Name

Smith

Date of Birth

Can you confirm you are 18 years or older?

Height

e.g. 5'8"

Weight

e.g. 170 lbs

2

Medical History

Please answer all questions as accurately as possible. Your provider will review this information.

Are you actively taking any medications? If so, please list them.

List all current medications, dosages, and frequencies

Do you have any medication allergies? If so, please list them.

List all known drug allergies and reactions

Are you currently being treated or have you been treated for any medical conditions? If so, please list them.

List all current and past medical conditions

Have you had any past surgeries? If so, please list them.

List all surgeries and approximate dates

What is/was your sex assigned at birth?

Male

Emergency contact name and phone number

Name — (555) 000-0000

Mailing address

123 Main St, City, State, ZIP

Any other questions or concerns?

Optional — share anything else you'd like your provider to know

3

Symptoms

Select all symptoms that currently apply to you.

Which of the following symptoms are you experiencing?
4

Medical Conditions

Select all conditions that currently apply to you.

Do any of the following apply to you?

Preview only. Your live form will include your branding and e-signature capture.

Submit

Compliance & Regulatory Notes

Review these notes before deploying this form in your practice.

LL-37 is not FDA-approved and is prescribed off-label. Documented informed consent is required. See FSMB: https://www.fsmb.org

LL-37 has immunomodulatory properties that may interact with biologic medications or immunosuppressants. Review all current medications before prescribing.

Patients with autoimmune disease require careful evaluation due to LL-37's complex immune effects. Consult rheumatology or immunology guidance as appropriate.

LL-37 must be dispensed by a licensed compounding pharmacy. See FDA: https://www.fda.gov/drugs/human-drug-compounding

Want This Form Automated?

Karpa Health turns static intake forms into a fully automated clinical workflow. Branded, HIPAA-compliant, and connected to compounding pharmacies.

  • Branded intake on your website
  • AI contraindication screening
  • One-click prescribing to pharmacies
  • Automated refill management
  • E-signatures and HIPAA audit trail
  • 50-state provider network included
Book a Demo

Free 30-minute walkthrough

Sources & References

  1. FDA Human Drug Compounding Guidance
  2. FSMB Off-Label Prescribing Guidelines
  3. NIH National Library of Medicine - LL-37

Frequently Asked Questions

How does LL-37 support immune function?

LL-37 is a cathelicidin peptide with broad antimicrobial activity against bacteria, viruses, and fungi. It also modulates inflammatory responses and supports wound healing by promoting tissue remodeling and angiogenesis.

Why is autoimmune disease a concern with LL-37?

LL-37 has been identified in elevated levels in certain autoimmune conditions (e.g., lupus, psoriasis). Its immunomodulatory effects could potentially exacerbate or alter autoimmune disease activity.